Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 May;32(6):565-70.
doi: 10.1055/s-0034-1543955. Epub 2015 Jan 16.

Rifampin Use and Safety in Hospitalized Infants

Affiliations
Free PMC article
Observational Study

Rifampin Use and Safety in Hospitalized Infants

Christopher J Arnold et al. Am J Perinatol. .
Free PMC article

Abstract

Objective: This study aims to examine the use and safety of rifampin in the hospitalized infants.

Study design: Observational study of clinical and laboratory adverse events among infants exposed to rifampin from 348 neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2012.

Result: Overall, 2,500 infants received 4,279 courses of rifampin; mean gestational age was 27 weeks (5th, 95th percentile; 23, 36) and mean birth weight was 1,125 g (515; 2,830). Thrombocytopenia (121/1,000 infant days) and conjugated hyperbilirubinemia (25/1,000 infant days) were the most common laboratory adverse events. The most common clinical adverse events were medical necrotizing enterocolitis (64/2,500 infants, 3%) and seizure (60/2,500 infants, 2%).

Conclusion: The overall incidence of adverse events among infants receiving rifampin appears low; however, additional studies to further evaluate safety and dosing of rifampin in this population are needed.

Conflict of interest statement

Conflicts of Interest

Dr. Hornik receives salary support for research from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) (UL1TR001117). Dr. Benjamin receives support from the United States government for his work in pediatric and neonatal clinical pharmacology (1R01HD057956-05, 1K24HD058735-05, UL1TR001117, and NICHD contract HHSN275201000003I) and the nonprofit organization Thrasher Research Fund for his work in neonatal candidiasis (www.thrasherresearch.org); he also receives research support from industry for neonatal and pediatric drug development (www.dcri.duke.edu/research/coi.jsp). Dr. Smith receives salary support for research from the NIH and the National Center for Advancing Translational Sciences of the NIH (HHSN267200700051C, HHSN275201000003I, and UL1TR001117); he also receives research support from industry for neonatal and pediatric drug development (www.dcri.duke.edu/research/coi.jsp). Dr. Ericson receives support from the National Institute of Child Health and Human Development of the NIH (5T32HD060558). The remaining authors have no potential conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Rifampin use over time. The red line indicates the mean number of infants exposed to rifampin during the study period.

Similar articles

See all similar articles

Cited by 2 articles

Publication types

MeSH terms

Feedback